Mateusz Lukaszyk

Dr. Mateusz Lukaszyk

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2015 in Kidney and Blood Pressure Research
Verified
Journal Article
Open access
EŁEwelina Łukaszyk
Ewelina Łukaszyk
MLMateusz Lukaszyk
Mateusz Lukaszyk
EKEwa Koc-Żórawska
Ewa Koc-Żórawska
JTJolanta Tobolczyk
Jolanta Tobolczyk
ABAnna Bodzenta-Łukaszyk
Anna Bodzenta-Łukaszyk
Jolanta MałyszkoJolanta Małyszko
Jolanta Małyszko
Background/Aims: One of the most common causes of anemia of chronic disease (ACD) is chronic kidney disease. The main pathomechanism responsible for ACD is subclinical inflammation. The key element involved in iron metabolism is hepcidin, however, studies on new indices of iron status are in progress.The aim of the study was to assess the iron status in patients in early stages of chronic kidney disease, iron correlation with inflammation parameters and novel biomarkers of iron metabolism. Methods: The study included 69 patients. Standard laboratory measurements were used to measure the iron status, complete blood count, fibrinogen, prothrombin index, C-reactive protein concentration (CRP), creatinine, urea, uric acid. Commercially available kits were used to measure high-sensitivity CRP, interleukin 6 (IL-6), hepcidin-25, hemojuvelin, soluble transferrin receptor (sTfR), growth differentiation factor-15 (GDF-15) and zonulin. Results: Absolute iron deficiency was present in 17% of the patients, functional iron deficiency was present in 12% of the patients. Functional iron deficiency was associated with significantly higher serum levels of fibrinogen, ferritin, transferrin saturation, total iron binding capacity, hepcidin and older age relative to patients with absolute iron deficiency. In comparison with patients without iron deficiency, patients with functional iron deficiency were older, with lower prothrombin index, higher fibrinogen, CRP, hsCRP, sTfR, GDF-15, urea and lower eGFR. Hepcidin was predicted by markers of inflammation:ferritin, fibrinogen and IL-6. Conclusion: Inflammation is correlated with iron status. Novel biomarkers of iron metabolism might be useful to distinguish iron deficiency anemia connected with inflammation and absolute iron deficiency.

4 April 2016 in International Urology and Nephrology
Verified
Journal Article
Open access
PDF file
EŁEwelina Łukaszyk
Ewelina Łukaszyk
MLMateusz Lukaszyk
Mateusz Lukaszyk
EKEwa Koc-Zorawska
Ewa Koc-Zorawska
ABAnna Bodzenta-Lukaszyk
Anna Bodzenta-Lukaszyk
Jolanta MałyszkoJolanta Małyszko
Jolanta Małyszko
The aim of the study was to assess GDF-15 and iron status in patients in early stages of chronic kidney disease with a particular emphasis on elderly population in association of classic iron status parameters with novel iron homeostasis biomarkers and inflammatory parameters.

13 November 2017 in International Urology and Nephrology
Verified
Journal Article
Open access
PDF file
EŁEwelina Łukaszyk
Ewelina Łukaszyk
MLMateusz Lukaszyk
Mateusz Lukaszyk
EKEwa Koc-Zorawska
Ewa Koc-Zorawska
ABAnna Bodzenta-Lukaszyk
Anna Bodzenta-Lukaszyk
Jolanta MałyszkoJolanta Małyszko
Jolanta Małyszko
Zonulin is the only known regulator of intestinal permeability. It is also considered as a potential inflammatory marker in several conditions such as diabetes and inflammatory bowel syndrome. The aim of the study was to investigate zonulin levels in patients with early stages of CKD and its possible correlation with inflammation, anemia and iron status parameters.

1 January 2014 in Advances in Dermatology and Allergology
Verified
Journal Article
Closed access
RSRoman Skiepko
Roman Skiepko
ZZZiemowit Ziętkowski
Ziemowit Ziętkowski
MLMateusz Lukaszyk
Mateusz Lukaszyk
WBWojciech Budny
Wojciech Budny
USUrszula Skiepko
Urszula Skiepko
ABAnna Bodzenta-Łukaszyk
Anna Bodzenta-Łukaszyk
Introduction : Omalizumab is a monoclonal anti-immunoglobulin E antibody developed for the treatment of severe allergic asthma. The number of exacerbations used as a parameter of omalizumab therapy efficacy may be insufficient in many cases due to a relatively short time to first evaluation...

1 January 2017 in Archives of Medical Science
Verified
Journal Article
Open access
EŁEwelina Łukaszyk
Ewelina Łukaszyk
MLMateusz Lukaszyk
Mateusz Lukaszyk
EKEwa Koc-Zorawska
Ewa Koc-Zorawska
ABAnna Bodzenta-Lukaszyk
Anna Bodzenta-Lukaszyk
Jolanta MałyszkoJolanta Małyszko
Jolanta Małyszko
Introduction: Fibroblast growth factor 23 (FGF-23) levels are elevated in impaired renal function. Inflammation and iron are potential regulators of FGF-23. The aim of the study was to evaluate the association between FGF-23 concentration, novel iron status biomarkers and inflammatory...

8 August 2022 in Clinical and Translational Allergy
Verified
Journal Article
Open access
SKStefan Kabasser
Stefan Kabasser
NCNadja Crvenjak
Nadja Crvenjak
SSStefanie Schmalz
Stefanie Schmalz
TKTanja Kalic
Tanja Kalic
CHChristine Hafner
Christine Hafner
MBMerima Bublin
Merima Bublin
Background: Almond allergy is common and can manifest in two different forms. Primary almond allergy has been reported to be associated with sensitization to almond legumin Pru du 6. In birchendemic regions, there is a link between birch‐pollinosis which is likely based on a cross‐reactive Bet v 1 homologue, a yet unidentified allergen in almond. Therefore, we sought to identify and characterize a Bet v 1‐homologue in almond.Methods: The expression of a Bet v 1 homologue in almond kernels was confirmed by mass spectrometry. The recombinant protein was produced in Escherichia coli and its cross‐reactivity and allergenic potency was analyzed by IgE quantitative and competitive ELISA, immunoblotting and basophil histamine release using sera from 17 almond allergic patients.Results: The identified Bet v 1 homologue received the designation Pru du 1.0101. Pru du 1.0101 bound IgE from 82 % of almond allergic patients. Bet v 1 was able to inhibit IgE‐binding to rPru du 1 by 100%, while rPru du 1 inhibited IgE binding to rBet v 1 by 48%. Pru du 1.0101 activated basophils, though 100‐ to 1000‐fold higher concentrations were required for maximum activation in comparison to rBet v 1.Conclusion: Considering the strong inhibition capacity and higher allergenic potency of Bet v 1, the results provide compelling evidence for primary sensitization to Bet v 1 in case of birch pollen associated almond allergy. Combining Pru du 6 and Pru du 1 in diagnostic approaches may help to discriminate between primary and birch‐pollen associated almond allergy.